TSE:CRDL

2.08
0.03 (1.46%) 1d
0
BUY
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
biotechnology
COMMENT
They struck a deal with Noramco, to sell into Canada and Mexico, synthetic CPD (for heart medication). They have enough cash to self finance the heart research.
biotechnology
HOLD
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year. This creates a great opportunity and they have enough technology to advance their strategy. If they can sell the CBC, the company is fairly valued.
biotechnology
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

Cardiol Therapeutics(CRDL-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Cardiol Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Cardiol Therapeutics(CRDL-T) Frequently Asked Questions

What is Cardiol Therapeutics stock symbol?

Cardiol Therapeutics is a Canadian stock, trading under the symbol CRDL-T on the Toronto Stock Exchange (CRDL-CT). It is usually referred to as TSX:CRDL or CRDL-T

Is Cardiol Therapeutics a buy or a sell?

In the last year, there was no coverage of Cardiol Therapeutics published on Stockchase.

Is Cardiol Therapeutics a good investment or a top pick?

Cardiol Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Cardiol Therapeutics.

Why is Cardiol Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Cardiol Therapeutics worth watching?

0 stock analysts on Stockchase covered Cardiol Therapeutics In the last year. It is a trending stock that is worth watching.

What is Cardiol Therapeutics stock price?

On 2024-12-06, Cardiol Therapeutics (CRDL-T) stock closed at a price of $2.08.